Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia: A Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 686
- 试验地点
- 82
- 主要终点
- Proportion of patients who die whithin 28 days or are still on invasive mechanical ventilation on day 28
研究概览
简要总结
Ventilator-associated pneumonia is the leading nosocomial infection in the intensive care units, and is associated with prolonged mechanical ventilation and overuse of antibiotics. Initiating antibiotic therapy immediately after bacteriological sampling (immediate strategy) may expose uninfected patients to unnecessary treatment, while waiting for bacteriological confirmation (conservative strategy) may delay ventilator-associated pneumonia in infected patients.
The decision to start antibiotic therapy for ventilator-associated pneumonia takes three points into account: diagnostic probability, the risks to the patient if Antibiotic Therapy is delayed, and the risk of selection of resistant bacteria. Diagnostic probability is limited, given the subjective and non-specific nature of the diagnostic criteria, and only 30-50% of suspected cases are confirmed bacteriologically (whereas samples are only taken when the pre-test probability is sufficient). The risks associated with delayed antibiotic therapy are unknown, as few observational studies have directly assessed the impact of the timing of Antibiotic Therapy initiation on outcome (frequent confusion between delayed and inappropriate Antibiotic Therapy).
Iregui et al. found that delaying Antibiotic Therapy by more than 24 hours was associated with higher mortality. However, more recent before-and-after studies have shown that the conservative strategy was associated with lower mortality, more frequently appropriate initial Antibiotic Therapy and shorter duration of Antibiotic Therapy. Similarly, in a recent before-and-after study by our team, initiating antibiotic therapy only upon microbiological confirmation of ventilator-associated pneumonia without septic shock or severe acute respiratory distress syndrome was not associated with an increase in ventilation time, length of stay or excess mortality at D28; but was associated with antibiotic therapy that was more often appropriate (DELAVAP, MARTIN et al, Annals of Intensive Care, 2024). Finally, the recent multicenter TARPP pilot study in surgical intensive care suggests that antibiotic therapy initiated on the basis of microbiological data in patients with suspected ventilator-associated pneumonia not requiring vasopressor support is not associated with a poorer outcome than immediate antibiotic therapy without documentation (the only randomized study on this subject).
Antibiotic Therapy for suspected ventilator-associated pneumonia that is not subsequently confirmed is an unnecessary use of antibiotics and carries a risk of selection of resistant bacteria, with adverse effects on public health. It has been reported that a conservative Antibiotic Therapy prescription strategy for intensive care units -acquired infections reduces Antibiotic Therapy use and the incidence of acquired β-lactamase-producing Enterobacteriaceae infections.
Overall, in patients with suspected ventilator-associated pneumonia but no signs of clinical severity, given the uncertainty about attributable mortality and concerns about bacterial resistance, the evaluation of the conservative Antibiotic Therapy strategy is reasonable. Some French intensive care units already delay Antibiotic Therapy until confirmation of ventilator-associated pneumonia, except in patients with severe hypoxemia or the need for vasopressor support.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Invasive mechanical ventilation for longer than 48 hours
- •Respiratory sample collection taken less than two hours ago (at physician discretion, according to local protocol) for a first episode of suspected ventilator-associated pneumonia (meeting the following prespecified criteria) :
- •new or changing chest X-ray infiltrates
- •plus at least two of the following:
- •body temperature ≥38°C or ≤35.5°C,
- •blood leukocyte count >12 000/µL or <4000/µL,
- •purulent tracheobronchial aspirate.
- •Age ≥18 years
- •Informed consent from the patient or next of kin to participation in the trial, or emergency procedure if no next of kin is available
- •Patients affiliated to a social security system
- •Non-inclusion Criteria:
- •Criteria for severe ventilator-associated pneumonia defined as:
- •Vasopressor therapy for onset of septic shock around the time of ventilator-associated pneumonia suspicion
- •Onset or severe worsening of hypoxemia (PaO2/FiO2<150 with 60% FiO2 and 10 mm H2O peak expiratory pressure, or patient on veno-venous extracorporeal membrane oxygenation)
- •Immunosuppression defined as :
- •leukocytes <1G/L or neutrophils <0,5 G/L
- •within the last 3 months
- •hematopoietic stem-cell transplant or organ transplant with chronic immunosuppressant therapy
- •HIV infection with CD4<50/mm3
- •chronic corticosteroid use (>0.5 mg/kg day for at least one month within the last three months).
- •Patient already on Antibiotic Therapy of predicted duration ≥4 weeks (endocarditis, spondylodiscitis, abscess...)
- •Previous ventilator-associated pneumonia suspicion with sampling and/or Antibiotic Therapy for suspected ventilator-associated pneumonia
- •Previous inclusion in the trial
- •Patient included in an interventional study on ventilator-associated pneumonia management with the same primary endpoint.
- •Pregnancy, recent delivery, or breastfeeding
- •Correctional facility inmate, adult under guardianship
- •Patient under legal protection
- •Life expectancy less than 48 h and/or decision not to treat potential pneumonia acquired under mechanical ventilation in the context of limiting/discontinuing treatment.
- •Organ donor reanimation
排除标准
- 未提供
研究组 & 干预措施
Immediate strategy
Usual Care
干预措施: control group (Procedure)
Conservative strategy
Conservative strategy
干预措施: Conservative strategy (Procedure)
结局指标
主要结局
Proportion of patients who die whithin 28 days or are still on invasive mechanical ventilation on day 28
时间窗: From day 0 to day 28
To assess, in intensive care units patients with suspected nonsevere ventilator-associated pneumonia (no septic shock or severe acute respiratory distress syndrome), whether delaying antibiotic therapy until ventilator-associated pneumonia is confirmed by a positive respiratory-sample culture and/or polymerase chain reaction test (conservative strategy) neither increases day-28 mortality nor prolongs invasive mechanical ventilation , compared to antibiotic therapy initiation immediately after sampling (immediate strategy).
次要结局
- Incidence of ventilator associated pneumonia related bacteria(From day 0 until the day of discharge from ICU, an average of 10 days)
- Descriptive bacteriological data(From day 0 to day 28)
- Descriptive clinical, laboratory and radiological data 48 hours before ventilator associated pneumonia suspicion(48 hours before ventilator asociated pneumonia suspicion)
- Proportion of patients with confirmed ventilator associated pneumonia(From day 0 to day 28)
- Incidence of ventilator associated pneumonia related abscess(From day 0 until the day of discharge from ICU, an average of 10 days)
- Sequential Organ Failure Assessment (SOFA) score(From day 0 to day 7)
- Modified clinical pulmonary infection score (mCPIS)(From day 0 to day 7)
- Clinical cure(day 7)
- Invasive mechanical ventilation duration(From day 0 to day 28)
- Ventilator free days(From day 0 to day 28)
- Use of vasopressors(From day 0 to day 28)
- Hospital stay lenghts(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidence and timing of subsequent ventilator associated pneumonia during the hospital stay(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidence of noscomial infections between randomisation and hospital discharge(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidence of in-hospital nosocomial infections by multiresistant bacteria (MRB)(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidences of allergies and of diarrhea(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Antibiotic-free days(day 10)
- Number of antibotic therapy days by day 28(day 28)
- Broad-spectrum days of therapy (DOT) by day 28(day 28)
- Carbapenom days of therapy (DOT) by day 28(day 28)
- Ventilator associated pneumonia antibiotic therapy(From day 0 to day 28)
- Descriptive antibiotic therapy data(From day 0 to day 28)
- Number of patients given active/inactive/unnecessary antibiotic therapy on day 0 and on the day of antibiotic therapy initiation(Day 0 and on the day of antibiotic therapy initiation, an average of 1 day)
- Number of patients with suitable antibotic therapy (defined as active antibiotic therapy or spared antibiotic therapy as defined below) on day 0 and on the day of antibiotic therapy initiation in the conservative strategy arm(Day 0 and on the day of antibiotic therapy initiation, until discharge from intensive care unit or up to 28 days)
- Incremental cost-utility ratio (ICUR)(day 90)
- Sequential Organ Failure Assessment (SOFA) score(From day 0 to day 7)
- Modified clinical pulmonary infection score (mCPIS)(From day 0 to day 7)
- Clinical cure(day 7)
- Invasive mechanical ventilation duration(From day 0 to day 28)
- Ventilator free days(From day 0 to day 28)
- Use of vasopressors(From day 0 to day 28)
- Use of renal replacement therapy(From day 0 to day 28)
- Mortality rates(Hospital discharge, an average of 20 days)
- ICU stay lenghts(From day 0 until the day of discharge from ICU, an average of 10 days)
- Hospital stay lenghts(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidence of ventilator associated pneumonia related abscess(From day 0 until the day of discharge from ICU, an average of 10 days)
- Incidence of ventilator associated pneumonia related bacteria(From day 0 until the day of discharge from ICU, an average of 10 days)
- Incidence and timing of subsequent ventilator associated pneumonia during the hospital stay(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidence of noscomial infections between randomisation and hospital discharge(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidence of in-hospital nosocomial infections by multiresistant bacteria (MRB)(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Incidences of allergies and of diarrhea(From day 0 until the day of discharge from Hospital, an average of 20 days)
- Antibiotic-free days(day 10)
- Number of antibotic therapy days by day 28(day 28)
- Broad-spectrum days of therapy (DOT) by day 28(day 28)
- Carbapenom days of therapy (DOT) by day 28(day 28)
- Ventilator associated pneumonia antibiotic therapy(From day 0 to day 28)
- Descriptive antibiotic therapy data(From day 0 to day 28)
- Descriptive bacteriological data(From day 0 to day 28)
- Descriptive clinical, laboratory and radiological data 48 hours before ventilator associated pneumonia suspicion(48 hours before ventilator asociated pneumonia suspicion)
- Proportion of patients with confirmed ventilator associated pneumonia(From day 0 to day 28)
- Number of patients given active/inactive/unnecessary antibiotic therapy on day 0 and on the day of antibiotic therapy initiation(Day 0 and on the day of antibiotic therapy initiation, an average of 1 day)
- Number of patients with suitable antibotic therapy (defined as active antibiotic therapy or spared antibiotic therapy as defined below) on day 0 and on the day of antibiotic therapy initiation in the conservative strategy arm(Day 0 and on the day of antibiotic therapy initiation, until discharge from intensive care unit or up to 28 days)
- Incremental cost-utility ratio (ICUR)(day 90)